Inmunómica traslacional en neoplasias hematológicas
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (4)
2023
-
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
2012
-
Phase i studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Investigational New Drugs, Vol. 30, Núm. 3, pp. 1121-1131
2007
-
The emerging role of targeted therapy for hematologic malignancies: Update on bortezomib and tipifarnib
Oncologist, Vol. 12, Núm. 3, pp. 281-290